A Pivotal Study to Evaluate the Bio-equivalence of the Tapentadol Extended-Release (ER) Tamper-resistant Formulation (TRF) Tablet to the Current Tapentadol ER Prolonged-release 2 (PR2) Tablet

Pas encore traduit Pas encore traduit
Catégorie Primary study
Registry of Trialsclinicaltrials.gov
Year 2010
The purpose of this study is to evaluate bio-equivalence of tapentadol extended-release (ER) tamper-resistant formulation (TRF) tablet, to the current tapentadol ER, prolonged-release formulation 2 (PR2) tablet, in healthy participants.
Epistemonikos ID: 9f9241243fa5a6779ee118891c9328af16b3e3fe
First added on: May 11, 2024